Browse CDH1

Summary
SymbolCDH1
Namecadherin 1, type 1
Aliases uvomorulin; CD324; E-Cadherin; UVO; cadherin 1, type 1, E-cadherin (epithelial); Arc-1; CDHE; ECAD; LCAM; CA ......
Chromosomal Location16q22.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cell junction Cell membrane Single-pass type I membrane protein. Endosome. Golgi apparatus, trans-Golgi network. Note=Colocalizes with DLGAP5 at sites of cell-cell contact in intestinal epithelial cells. Anchored to actin microfilaments through association with alpha-, beta- and gamma-catenin. Sequential proteolysis induced by apoptosis or calcium influx, results in translocation from sites of cell-cell contact to the cytoplasm. Colocalizes with RAB11A endosomes during its transport from the Golgi apparatus to the plasma membrane.
Domain PF00028 Cadherin domain
PF01049 Cadherin cytoplasmic region
PF08758 Cadherin prodomain like
Function

Cadherins are calcium-dependent cell adhesion proteins (PubMed:11976333). They preferentially interact with themselves in a homophilic manner in connecting cells; cadherins may thus contribute to the sorting of heterogeneous cell types. CDH1 is involved in mechanisms regulating cell-cell adhesions, mobility and proliferation of epithelial cells (PubMed:11976333). Has a potent invasive suppressor role. It is a ligand for integrin alpha-E/beta-7. ; FUNCTION: E-Cad/CTF2 promotes non-amyloidogenic degradation of Abeta precursors. Has a strong inhibitory effect on APP C99 and C83 production.

> Gene Ontology
 
Biological Process GO:0006606 protein import into nucleus
GO:0006913 nucleocytoplasmic transport
GO:0007009 plasma membrane organization
GO:0007156 homophilic cell adhesion via plasma membrane adhesion molecules
GO:0007162 negative regulation of cell adhesion
GO:0007416 synapse assembly
GO:0009636 response to toxic substance
GO:0010035 response to inorganic substance
GO:0010038 response to metal ion
GO:0010226 response to lithium ion
GO:0017038 protein import
GO:0021536 diencephalon development
GO:0021983 pituitary gland development
GO:0022407 regulation of cell-cell adhesion
GO:0022408 negative regulation of cell-cell adhesion
GO:0022617 extracellular matrix disassembly
GO:0030198 extracellular matrix organization
GO:0030900 forebrain development
GO:0032386 regulation of intracellular transport
GO:0032388 positive regulation of intracellular transport
GO:0033157 regulation of intracellular protein transport
GO:0034330 cell junction organization
GO:0034332 adherens junction organization
GO:0034504 protein localization to nucleus
GO:0035270 endocrine system development
GO:0042306 regulation of protein import into nucleus
GO:0042307 positive regulation of protein import into nucleus
GO:0042493 response to drug
GO:0042990 regulation of transcription factor import into nucleus
GO:0042991 transcription factor import into nucleus
GO:0042993 positive regulation of transcription factor import into nucleus
GO:0043062 extracellular structure organization
GO:0044744 protein targeting to nucleus
GO:0045216 cell-cell junction organization
GO:0046822 regulation of nucleocytoplasmic transport
GO:0046824 positive regulation of nucleocytoplasmic transport
GO:0048732 gland development
GO:0050808 synapse organization
GO:0051169 nuclear transport
GO:0051170 nuclear import
GO:0051222 positive regulation of protein transport
GO:0071241 cellular response to inorganic substance
GO:0071248 cellular response to metal ion
GO:0071285 cellular response to lithium ion
GO:0071407 cellular response to organic cyclic compound
GO:0071417 cellular response to organonitrogen compound
GO:0071680 response to indole-3-methanol
GO:0071681 cellular response to indole-3-methanol
GO:0072657 protein localization to membrane
GO:0072659 protein localization to plasma membrane
GO:0090002 establishment of protein localization to plasma membrane
GO:0090150 establishment of protein localization to membrane
GO:0090316 positive regulation of intracellular protein transport
GO:0097305 response to alcohol
GO:0097306 cellular response to alcohol
GO:0098742 cell-cell adhesion via plasma-membrane adhesion molecules
GO:1900180 regulation of protein localization to nucleus
GO:1900182 positive regulation of protein localization to nucleus
GO:1902593 single-organism nuclear import
GO:1903533 regulation of protein targeting
GO:1903829 positive regulation of cellular protein localization
GO:1904589 regulation of protein import
GO:1904591 positive regulation of protein import
GO:1904951 positive regulation of establishment of protein localization
GO:1990778 protein localization to cell periphery
Molecular Function GO:0001948 glycoprotein binding
GO:0008013 beta-catenin binding
GO:0030506 ankyrin binding
GO:0032794 GTPase activating protein binding
GO:0045295 gamma-catenin binding
GO:0045296 cadherin binding
GO:0050839 cell adhesion molecule binding
GO:0098631 protein binding involved in cell adhesion
GO:0098632 protein binding involved in cell-cell adhesion
GO:0098641 cadherin binding involved in cell-cell adhesion
Cellular Component GO:0005802 trans-Golgi network
GO:0005901 caveola
GO:0005913 cell-cell adherens junction
GO:0005924 cell-substrate adherens junction
GO:0005925 focal adhesion
GO:0005938 cell cortex
GO:0009898 cytoplasmic side of plasma membrane
GO:0015629 actin cytoskeleton
GO:0016234 inclusion body
GO:0016235 aggresome
GO:0016328 lateral plasma membrane
GO:0016342 catenin complex
GO:0016600 flotillin complex
GO:0019897 extrinsic component of plasma membrane
GO:0019898 extrinsic component of membrane
GO:0030027 lamellipodium
GO:0030055 cell-substrate junction
GO:0030863 cortical cytoskeleton
GO:0030864 cortical actin cytoskeleton
GO:0031252 cell leading edge
GO:0031984 organelle subcompartment
GO:0043296 apical junction complex
GO:0044448 cell cortex part
GO:0044853 plasma membrane raft
GO:0045121 membrane raft
GO:0098552 side of membrane
GO:0098562 cytoplasmic side of membrane
GO:0098589 membrane region
GO:0098791 Golgi subcompartment
GO:0098857 membrane microdomain
GO:0099568 cytoplasmic region
> KEGG and Reactome Pathway
 
KEGG hsa04015 Rap1 signaling pathway
hsa04390 Hippo signaling pathway
hsa04514 Cell adhesion molecules (CAMs)
hsa04520 Adherens junction
Reactome R-HSA-1280218: Adaptive Immune System
R-HSA-418990: Adherens junctions interactions
R-HSA-109581: Apoptosis
R-HSA-351906: Apoptotic cleavage of cell adhesion proteins
R-HSA-111465: Apoptotic cleavage of cellular proteins
R-HSA-75153: Apoptotic execution phase
R-HSA-446728: Cell junction organization
R-HSA-1500931: Cell-Cell communication
R-HSA-421270: Cell-cell junction organization
R-HSA-1474228: Degradation of the extracellular matrix
R-HSA-1643685: Disease
R-HSA-1474244: Extracellular matrix organization
R-HSA-168256: Immune System
R-HSA-198933: Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell
R-HSA-5663205: Infectious disease
R-HSA-8876493: InlA-mediated entry of Listeria monocytogenes into host cells
R-HSA-216083: Integrin cell surface interactions
R-HSA-8876384: Listeria monocytogenes entry into host cells
R-HSA-5357801: Programmed Cell Death
R-HSA-195258: RHO GTPase Effectors
R-HSA-5626467: RHO GTPases activate IQGAPs
R-HSA-162582: Signal Transduction
R-HSA-194315: Signaling by Rho GTPases
Summary
SymbolCDH1
Namecadherin 1, type 1
Aliases uvomorulin; CD324; E-Cadherin; UVO; cadherin 1, type 1, E-cadherin (epithelial); Arc-1; CDHE; ECAD; LCAM; CA ......
Chromosomal Location16q22.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between CDH1 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.
Summary
SymbolCDH1
Namecadherin 1, type 1
Aliases uvomorulin; CD324; E-Cadherin; UVO; cadherin 1, type 1, E-cadherin (epithelial); Arc-1; CDHE; ECAD; LCAM; CA ......
Chromosomal Location16q22.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of CDH1 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolCDH1
Namecadherin 1, type 1
Aliases uvomorulin; CD324; E-Cadherin; UVO; cadherin 1, type 1, E-cadherin (epithelial); Arc-1; CDHE; ECAD; LCAM; CA ......
Chromosomal Location16q22.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of CDH1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14123.7020.000113
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)654.5240.056
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)873.1190.07
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.4990.376
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.6430.797
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-0.3210.916
729033130MelanomaallAnti-PD-1 (nivolumab) 2623-1.6460.143
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.3330.869
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-3.8450.0711
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.7490.628
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.2480.913
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.060.729
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of CDH1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277301.4-1.41
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275901.7-1.71
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91622.2022.20.12
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59200200.357
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47250250.364
1329033130MelanomaallAnti-PD-1 (nivolumab) 38270001
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolCDH1
Namecadherin 1, type 1
Aliases uvomorulin; CD324; E-Cadherin; UVO; cadherin 1, type 1, E-cadherin (epithelial); Arc-1; CDHE; ECAD; LCAM; CA ......
Chromosomal Location16q22.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of CDH1. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolCDH1
Namecadherin 1, type 1
Aliases uvomorulin; CD324; E-Cadherin; UVO; cadherin 1, type 1, E-cadherin (epithelial); Arc-1; CDHE; ECAD; LCAM; CA ......
Chromosomal Location16q22.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of CDH1. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by CDH1.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolCDH1
Namecadherin 1, type 1
Aliases uvomorulin; CD324; E-Cadherin; UVO; cadherin 1, type 1, E-cadherin (epithelial); Arc-1; CDHE; ECAD; LCAM; CA ......
Chromosomal Location16q22.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of CDH1. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolCDH1
Namecadherin 1, type 1
Aliases uvomorulin; CD324; E-Cadherin; UVO; cadherin 1, type 1, E-cadherin (epithelial); Arc-1; CDHE; ECAD; LCAM; CA ......
Chromosomal Location16q22.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of CDH1 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolCDH1
Namecadherin 1, type 1
Aliases uvomorulin; CD324; E-Cadherin; UVO; cadherin 1, type 1, E-cadherin (epithelial); Arc-1; CDHE; ECAD; LCAM; CA ......
Chromosomal Location16q22.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between CDH1 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolCDH1
Namecadherin 1, type 1
Aliases uvomorulin; CD324; E-Cadherin; UVO; cadherin 1, type 1, E-cadherin (epithelial); Arc-1; CDHE; ECAD; LCAM; CA ......
Chromosomal Location16q22.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting CDH1 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.